FDA clears drug for bladder control from UCB, Pfizer

11/3/2008 | Bloomberg · WebMD

The FDA granted approval for Toviaz, a once-daily drug from UCB and Pfizer designed to treat adults with overactive bladders. The clearance is based on two 12-week trials showing the medicine's efficacy versus placebo in decreasing urinary frequency. Pfizer paid as much as $210 million in April 2006 to secure the U.S. rights to Toviaz from Schwarz Pharma of Germany.

View Full Article in:

Bloomberg · WebMD

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ